Talazoparib for BRCA-mutated advanced breast cancer

被引：4
|
作者：
Gunjur, Ashray
机构：
来源：
LANCET ONCOLOGY | 2018年 / 19卷 / 10期
关键词：
D O I：
10.1016/S1470-2045(18)30650-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E511 / E511
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study
    Haruru Kotani
    Norikazu Masuda
    Toshinari Yamashita
    Yoichi Naito
    Tetsuhiko Taira
    Kenichi Inoue
    Masato Takahashi
    Kan Yonemori
    Shigeyuki Toyoizumi
    Yuko Mori
    Takashi Nagasawa
    Natsuki Hori
    Hiroji Iwata
    Breast Cancer, 2022, 29 : 1088 - 1098
  • [22] Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study
    Kotani, Haruru
    Masuda, Norikazu
    Yamashita, Toshinari
    Naito, Yoichi
    Taira, Tetsuhiko
    Inoue, Kenichi
    Takahashi, Masato
    Yonemori, Kan
    Toyoizumi, Shigeyuki
    Mori, Yuko
    Nagasawa, Takashi
    Hori, Natsuki
    Iwata, Hiroji
    BREAST CANCER, 2022, 29 (06) : 1088 - 1098
  • [23] Immune profiling of BRCA-mutated breast cancers
    Force, Jeremy Meyer
    Abbott, Sarah
    Broadwater, Gloria
    Stashko, Ilona
    Westbrook, Kelly E.
    Kimmick, Gretchen Genevieve
    Sammons, Sarah LeNoir
    Hyslop, Terry
    Brauer, Heather Ann
    Mashadi-Hossein, Afshin
    Plichta, Jennifer Kay
    Hwang, Eun-Sil Shelley
    Kauff, Noah D.
    Weinhold, Kent J.
    Nair, Smita
    Castellar, Edgardo
    Marcom, Paul Kelly
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Germline BRCA-mutated metastatic breast cancer with positive hormone receptor
    Palleschi, Michela
    Iaia, Maria Laura
    Casadei, Chiara
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (01) : 265 - 266
  • [25] Germline BRCA-mutated metastatic breast cancer with positive hormone receptor
    Michela Palleschi
    Maria Laura Iaia
    Chiara Casadei
    Breast Cancer Research and Treatment, 2021, 186 : 265 - 266
  • [26] Brain metastasis in patients with hereditary BRCA-mutated invasive breast cancer
    Garber, Haven
    Raghavendra, Akshara Singareeka
    Hess, Kenneth R.
    Arun, Banu
    Ibrahim, Nuhad K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
    Litton, Jennifer K.
    Rugo, Hope S.
    Ettl, Johannes
    Hurvitz, Sara A.
    Goncalves, Anthony
    Lee, Kyung-Hun
    Fehrenbacher, Louis
    Yerushalmi, Rinat
    Mina, Lida A.
    Martin, Miguel
    Roche, Henri
    Im, Young-Hyuck
    Quek, Ruben G. W.
    Markova, Denka
    Tudor, Iulia C.
    Hannah, Alison L.
    Eiermann, Wolfgang
    Blum, Joanne L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (08): : 753 - 763
  • [28] PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis
    Yan, Feifei
    Jiang, Qi
    He, Mengye
    Shen, Peng
    FUTURE ONCOLOGY, 2021, 17 (18) : 2381 - 2393
  • [29] PARP inhibition in BRCA-mutated breast and ovarian cancers
    Chan, Stephen L.
    Mok, Tony
    LANCET, 2010, 376 (9737): : 211 - 213
  • [30] Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer
    Le, Dan
    Gelmon, Karen A.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (09) : 833 - 839
12345